{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:54Z","timestamp":1794047454452,"version":"4.8.0"},"reference-count":28,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>STAT5B has been reported as a recurrent mutation in myeloid neoplasms with eosinophilia, but its overall frequency and importance across a spectrum of myeloid neoplasms are largely unknown. We conducted a multicenter study on a series of 82 myeloid neoplasms with STAT5B mutations detected by next-generation sequencing. The estimated frequency of STAT5B mutations in myeloid neoplasms was low, &lt;0.5%, but mutations were detected in all categories of such neoplasms, including myelodysplastic syndrome (MDS, 28%), acute myeloid leukemia (AML, 26%), myelodysplastic\/myeloproliferative neoplasm (MDS\/MPN, 18%), Philadelphia chromosome-negative classic MPN (12%), systemic mastocytosis (1%), and, with a notably high frequency, chronic eosinophilic leukemia, not otherwise specified (CEL-NOS, 15%). STAT5B mutations occurred preferentially in the SH2 domain (95%), involved 12 different codons, with the N642H hotspot being the most common (78%). Co-mutations were present in all cases and clonal hierarchy analysis showed that STAT5B mutations tended to be subclonal in AML, MPN, and MDS, but frequently dominant\/co-dominant in CEL-NOS (83%), followed by MDS\/MPN (40%). Across the group, eosinophilia and\/or basophilia were common (41%), frequently observed in cases in which STAT5B mutations were detected at initial diagnosis (P&lt;0.0001), with a high variant allele frequency (median 42.5%, P=0.0001), as a dominant\/ co-dominant clone (P&lt;0.0001), involving the canonical N642H (P=0.0607), and associated with fewer co-mutations (P=0.0009). Our data show that the characteristics and importance of a STAT5B mutation differ among myeloid neoplasms, but if present as a dominant mutation and detected at initial diagnosis, it appears to be a driver mutation in a subgroup of chronic myeloid neoplasms, preferentially promoting a proliferation of eosinophils and basophils.<\/jats:p>","DOI":"10.3324\/haematol.2023.284311","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T02:31:30Z","timestamp":1700101890000},"page":"1825-1835","source":"Crossref","is-referenced-by-count":9,"title":["&lt;i&gt;STAT5B&lt;\/i&gt; mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and\/or basophilia"],"prefix":"10.3324","volume":"109","author":[{"given":"C. Cameron","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu M.","family":"Ouseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"K.Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Routbort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"62011","doi-asserted-by":"crossref","unstructured":"de Araujo ED, Erdogan F, Neubauer HA. Structural and functional consequences of the STAT5B(N642H) driver mutation. Nat Commun. 2019; 10(1):2517.","DOI":"10.1038\/s41467-019-10422-7"},{"key":"62012","doi-asserted-by":"crossref","unstructured":"Halim CE, Deng S, Ong MS, Yap CT. Involvement of STAT5 in oncogenesis. Biomedicines. 2020; 8(9):316.","DOI":"10.3390\/biomedicines8090316"},{"key":"62013","doi-asserted-by":"crossref","unstructured":"Smith MR, Satter LRF, Vargas-Hernandez A. STAT5b: a master regulator of key biological pathways. Front Immunol. 2022; 13:1025373.","DOI":"10.3389\/fimmu.2022.1025373"},{"key":"62014","doi-asserted-by":"crossref","unstructured":"Pham HTT, Maurer B, Prchal-Murphy M. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018; 128(1):387-401.","DOI":"10.1172\/JCI94509"},{"key":"62015","doi-asserted-by":"crossref","unstructured":"Bhattacharya D, Teramo A, Gasparini VR. Identification of novel STAT5B mutations and characterization of TCRbeta signatures in CD4+ T-cell large granular lymphocyte leukemia. Blood Cancer J. 2022; 12(2):31.","DOI":"10.1038\/s41408-022-00630-8"},{"key":"62016","doi-asserted-by":"crossref","unstructured":"Rajala HL, Eldfors S, Kuusanmaki H. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121(22):4541-4550.","DOI":"10.1182\/blood-2012-12-474577"},{"key":"62017","doi-asserted-by":"crossref","unstructured":"Wahnschaffe L, Braun T, Timonen S. JAK\/STAT-activating genomic alterations are a hallmark of T-PLL. Cancers (Basel). 2019; 11(12):1833.","DOI":"10.3390\/cancers11121833"},{"key":"62018","doi-asserted-by":"crossref","unstructured":"Kucuk C, Jiang B, Hu X. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015; 6:6025.","DOI":"10.1038\/ncomms7025"},{"key":"62019","doi-asserted-by":"crossref","unstructured":"Bandapalli OR, Schuessele S, Kunz JB. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica. 2014; 99(10):e188-192.","DOI":"10.3324\/haematol.2014.104992"},{"key":"62020","doi-asserted-by":"crossref","unstructured":"Maurer B, Kollmann S, Pickem J, Hoelbl-Kovacic A, Sexl V. STAT5A and STAT5B - twins with different personalities in hematopoiesis and leukemia. Cancers (Basel). 2019; 11(11):1726.","DOI":"10.3390\/cancers11111726"},{"key":"62021","doi-asserted-by":"crossref","unstructured":"Cross NCP, Hoade Y, Tapper WJ. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2019; 33(2):415-425.","DOI":"10.1038\/s41375-018-0342-3"},{"key":"62022","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005; 90(8):1128-1132."},{"key":"62023","doi-asserted-by":"crossref","unstructured":"Palomo L, Meggendorfer M, Hutter S. Molecular landscape and clonal architecture of adult myelodysplastic\/ myeloproliferative neoplasms. Blood. 2020; 136(16):1851-1862.","DOI":"10.1182\/blood.2019004229"},{"key":"62024","doi-asserted-by":"crossref","unstructured":"Valent P, Sotlar K, Blatt K. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia. 2017; 31(4):788-797.","DOI":"10.1038\/leu.2017.15"},{"key":"62025","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"62026","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"62027","doi-asserted-by":"crossref","unstructured":"Umrau K, Naganuma K, Gao Q. Activating STAT5B mutations can cause both primary hypereosinophilia and lymphocyte-variant hypereosinophilia. Leuk Lymphoma. 2023; 64(1):238-241.","DOI":"10.1080\/10428194.2022.2131413"},{"key":"62028","doi-asserted-by":"crossref","unstructured":"Andersson EI, Putzer S, Yadav B. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia. 2018; 32(3):774-787.","DOI":"10.1038\/leu.2017.252"},{"key":"62029","doi-asserted-by":"crossref","unstructured":"Sreedharanunni S, Jamwal M, Balakrishnan A. Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-an entity with features of myelodysplastic syndrome\/ myeloproliferative neoplasm overlap. Leuk Res. 2022; 112:106753.","DOI":"10.1016\/j.leukres.2021.106753"},{"key":"62030","doi-asserted-by":"crossref","unstructured":"Ruan GJ, Smith CJ, Day C. A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. Am J Hematol. 2020; 95(10):E257-E260.","DOI":"10.1002\/ajh.25906"},{"key":"62031","doi-asserted-by":"crossref","unstructured":"Srour SA, Devesa SS, Morton LM. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/ myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016; 174(3):382-396.","DOI":"10.1111\/bjh.14061"},{"key":"62032","doi-asserted-by":"crossref","unstructured":"Hu Z, Boddu PC, Loghavi S. A multimodality work-up of patients with hypereosinophilia. Am J Hematol. 2018; 93(11):1337-1346.","DOI":"10.1002\/ajh.25247"},{"key":"62033","doi-asserted-by":"crossref","unstructured":"Wang SA, Hasserjian RP, Tam W. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017; 102(8):1352-1360.","DOI":"10.3324\/haematol.2017.165340"},{"key":"62034","doi-asserted-by":"crossref","unstructured":"Wang SA, Tam W, Tsai AG. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016; 29(8):854-864.","DOI":"10.1038\/modpathol.2016.75"},{"key":"62035","doi-asserted-by":"crossref","unstructured":"Kelemen K, Saft L, Craig FE. Eosinophilia\/ hypereosinophilia in the setting of reactive and idiopathic causes, well-defined myeloid or lymphoid leukemias, or germline disorders. Am J Clin Pathol. 2021; 155(2):179-210.","DOI":"10.1093\/ajcp\/aqaa244"},{"key":"62036","doi-asserted-by":"crossref","unstructured":"Li Y, Qi X, Liu B, Huang H. The STAT5-GATA2 pathway is critical in basophil and mast cell differentiation and maintenance. J Immunol. 2015; 194(9):4328-4338.","DOI":"10.4049\/jimmunol.1500018"},{"key":"62037","doi-asserted-by":"crossref","unstructured":"Pozdnyakova O, Orazi A, Kelemen K. Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or w.ith PCM1-JAK2. Am J Clin Pathol. 2021; 155(2):160-178.","DOI":"10.1093\/ajcp\/aqaa208"},{"key":"62038","doi-asserted-by":"crossref","unstructured":"Eisenberg R, Gans MD, Leahy TR. JAK inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease. J Allergy Clin Immunol Pract. 2021; 9(2):1008-1010.e2.","DOI":"10.1016\/j.jaip.2020.11.050"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284311\/76288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284311\/77062","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11340\/76288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:16Z","timestamp":1794045916000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284311","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}